Literature DB >> 30878968

Seronegative neuromyelitis optica spectrum disorder: severe polysymptomatic presentation with successful treatment response.

Gilberto Pires da Rosa1, Francisca Costa2, Joana Guimarães3,4, Fernando Friões1,5.   

Abstract

We report the case of a 50-year-old caucasian man presenting with lumbar pain, bilateral ataxia, central facial palsy, ophthalmoparesis and urinary retention. Cerebral MRI hinted a hyperintensity of the medulla oblongata and cervical medulla suggestive of myelitis. Cerebrospinal fluid displayed lymphocytic pleocytosis and elevated protein concentration. Without the possibility to rule out an infectious or inflammatory aetiology, antibiotics and corticosteroids were started. Nevertheless, neurological status deteriorated with loss of muscle strength and left eye amaurosis. A neuroaxis MRI exhibited encephalomyelitis with signal abnormalities involving the pons, medulla oblongata, left optic nerve and cervicodorsal medulla. Although negative for aquaporin-4-IgG antibodies, the patient fulfilled criteria for seronegative neuromyelitis optica spectrum disorder with the presence of multiple core clinical characteristics. Through early institution of corticosteroids, plasma exchange and rituximab, good functional recovery was achieved (Expanded Disability Status Scale score of 2). However, left eye amaurosis persisted despite salvage therapy with intravenous immunoglobulin. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  brain stem / cerebellum; immunology; neuroimaging; neurology; spinal cord

Mesh:

Substances:

Year:  2019        PMID: 30878968      PMCID: PMC6424383          DOI: 10.1136/bcr-2018-228553

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  21 in total

1.  A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.

Authors:  J H Noseworthy; P C O'Brien; T M Petterson; J Weis; L Stevens; W K Peterson; D Sneve; S A Cross; J A Leavitt; R G Auger; B G Weinshenker; D W Dodick; D M Wingerchuk; M Rodriguez
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

2.  Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes.

Authors:  Akiko Nagaishi; Mineo Takagi; Atsushi Umemura; Masami Tanaka; Yoko Kitagawa; Makoto Matsui; Masatoyo Nishizawa; Kenji Sakimura; Keiko Tanaka
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-06-10       Impact factor: 10.154

Review 3.  Neuromyelitis optica and neuromyelitis optica spectrum disorders.

Authors:  Romain Marignier; Alvaro Cobo Calvo; Sandra Vukusic
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

4.  Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.

Authors:  Joanna Kitley; M Isabel Leite; Ichiro Nakashima; Patrick Waters; Benjamin McNeillis; Rachel Brown; Yoshiki Takai; Toshiyuki Takahashi; Tatsuro Misu; Liene Elsone; Mark Woodhall; Jithin George; Mike Boggild; Angela Vincent; Anu Jacob; Kazuo Fujihara; Jacqueline Palace
Journal:  Brain       Date:  2012-05-09       Impact factor: 13.501

5.  Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status.

Authors:  Yazhuo Kong; Helen Okoruwa; Jon Revis; George Tackley; Maria Isabel Leite; Michael Lee; Irene Tracey; Jacqueline Palace
Journal:  J Neurol Sci       Date:  2016-06-23       Impact factor: 3.181

6.  Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.

Authors:  Velina S Chavarro; Maureen A Mealy; Alexandra Simpson; Anna Lacheta; Florence Pache; Klemens Ruprecht; Stefan M Gold; Friedemann Paul; Alexander Ulrich Brandt; Michael Levy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-10-24

Review 7.  Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.

Authors:  Frederike C Oertel; Hanna Zimmermann; Friedemann Paul; Alexander U Brandt
Journal:  EPMA J       Date:  2017-12-22       Impact factor: 6.543

Review 8.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

Review 9.  Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis.

Authors:  Valentina Damato; Amelia Evoli; Raffaele Iorio
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

10.  Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Authors:  Ingo Kleiter; Anna Gahlen; Nadja Borisow; Katrin Fischer; Klaus-Dieter Wernecke; Kerstin Hellwig; Florence Pache; Klemens Ruprecht; Joachim Havla; Tania Kümpfel; Orhan Aktas; Hans-Peter Hartung; Marius Ringelstein; Christian Geis; Christoph Kleinschnitz; Achim Berthele; Bernhard Hemmer; Klemens Angstwurm; Jan-Patrick Stellmann; Simon Schuster; Martin Stangel; Florian Lauda; Hayrettin Tumani; Christoph Mayer; Markus Krumbholz; Lena Zeltner; Ulf Ziemann; Ralf Linker; Matthias Schwab; Martin Marziniak; Florian Then Bergh; Ulrich Hofstadt-van Oy; Oliver Neuhaus; Uwe K Zettl; Jürgen Faiss; Brigitte Wildemann; Friedemann Paul; Sven Jarius; Corinna Trebst
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-09-26
View more
  1 in total

1.  Seronegative Neuromyelitis Optica Spectrum Disorder: An Unusual Presentation of Acute Brainstem Syndrome.

Authors:  Zahra Haider Alshurafa; Mashael Omar Alkhateeb
Journal:  Am J Case Rep       Date:  2020-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.